Merck SharpDohme LLC
Rescue Medication(Merck Sharp & Dohme LLC)은 Triple Negative Breast Neoplasms 표적 ADC로, Non Small Cell Lung Cancer 영역에서 개발·상용화 중입니다. 작용기전: inhibits the Wnt signaling pathway. Phase 3 후기 임상 단계입니다. ClinicalTrials.gov 기준 69건의 관련 임상이 등록되어 있습니다. 차별점: novel formulation of semaglutide injection: A multicentre, randomized, comparative, active controlled, phase 3 study in compa.
Triple Negative Breast Neoplasms
Non Small Cell Lung Cancer
Recruiting
retroviral therapy
novel formulation of semaglutide injection: A multicentre, randomized, comparative, active controlled, phase 3 study in compa
inhibits the Wnt signaling pathway
apoptosis, migration, and autophagy of ovarian cancer cells
biomarker associated with adverse clinical outcomes in HCC
Downregulation of miR-6721-5p in the serum of patients with spinal cord injury and its role in regulating microglial inflammation via
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Merck SharpDohme LLC
Rescue Medication(Merck Sharp & Dohme LLC)은 Triple Negative Breast Neoplasms 표적 ADC로, Non Small Cell Lung Cancer 영역에서 개발·상용화 중입니다. 작용기전: inhibits the Wnt signaling pathway. Phase 3 후기 임상 단계입니다. ClinicalTrials.gov 기준 69건의 관련 임상이 등록되어 있습니다. 차별점: novel formulation of semaglutide injection: A multicentre, randomized, comparative, active controlled, phase 3 study in compa.
Triple Negative Breast Neoplasms
Non Small Cell Lung Cancer
Recruiting
retroviral therapy
novel formulation of semaglutide injection: A multicentre, randomized, comparative, active controlled, phase 3 study in compa
inhibits the Wnt signaling pathway
apoptosis, migration, and autophagy of ovarian cancer cells
biomarker associated with adverse clinical outcomes in HCC
Downregulation of miR-6721-5p in the serum of patients with spinal cord injury and its role in regulating microglial inflammation via
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.